

CURRICULUM VITAE AND BIBLIOGRAPHY

Date of preparation: July 20th, 2016

A. GENERAL INFORMATION

1. NAME: Jason T. Huse, M.D., Ph.D.
2. OFFICE ADDRESS: Sloan-Kettering Institute TEL #: 646-888-2055
408 E. 69th St.(Z564) FAX #: none
New York, NY 10065

B. EDUCATIONAL BACKGROUND

1. Degree

Degree	Institution	Dates Attended	Date Awarded
B.A.	Princeton University Princeton, NJ	09/1992-06/1996	06/1996
M.D., Ph.D	University of Pennsylvania School of Medicine Philadelphia, PA	08/1996-05/2003	05/2003

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training

<u>Title</u>	<u>Institution</u>	<u>Dates held</u>
Resident, Pathology	Hospital of the University of Pennsylvania Philadelphia, PA	07/2003-06/2005
Fellow in Neuropathology	Hospital of the University of Pennsylvania Philadelphia, PA	07/2005-06/2007
Research Fellow	Sloan-Kettering Institute Memorial Sloan-Kettering Cancer Center New York, NY	09/2006-06/2009

2. Academic Positions

- Assistant Member, Department of Pathology, Leon Levy Foundation Young Investigator, Memorial Hospital for Cancer and Allied Diseases; 07/2009-present
- Assistant Member, Human Oncology and Pathogenesis Program; 07/2013-present

3. Hospital Positions

- Instructor, Department of Pathology, Memorial Hospital for Cancer and Allied Diseases; 10/2008-06/2009
- Assistant Attending, Department of Pathology, Memorial Hospital for Cancer and Allied Diseases; 07/2009-present

D. LICENSURE, BOARD CERTIFICATION

1. Licensure

- | a. State | Date of Issue | Last Registration |
|----------------|---------------|-------------------|
| New York State | 8/12/08 | 12/31/15 |
| Pennsylvania | 2/2/07 | 2/2/07 |
- b. If no license: N/A
c. DEA number: N/A
d. NPI number: 1457426306

New York (Active)
Pennsylvania (Inactive)
Texas (pending)

2. Board Certification

<u>Board</u>	<u>Date</u>
Anatomic Pathology American Board of Pathology	09/20/2007
Neuropathology American Board of Pathology	09/20/2007

E. PROFESSIONAL MEMBERSHIPS

College of American Pathologists
American Association for Cancer Research
American Association of Neuropathologists
Society for Neuro-oncology
American Society of Clinical Oncology
Pediatric Brain Tumor Consortium
Neuroplex-The New York Association of Neuropathologists

F. HONORS AND AWARDS:

<u>Name</u>	<u>Date Awarded</u>
Sontag Foundation Distinguished Scientist Award	10/2012
Doris Duke Clinical Scientist Development Award	07/2012
Sidney Kimmel Translational Science Award	07/2012

AACR-Landon Innovator Award for Research in Personalized Cancer Medicine	04/2011
Leon Levy Foundation Young Investigator	07/2009
Weil Award for the Best Paper in Experimental Neuropathology (AANP Meeting)	06/2009
Revson/Winston Fellow in Biomedical Research	07/2009
David Tetenbaum Hope/American Brain Tumor Association Fellow	07/2006
Louise B. Flexner Student Prize for Outstanding Dissertation	10/2002
Saul Wingrad Award for Outstanding Dissertation	05/2002
Jesse H. Frank Prize in Pathology	05/2003
Robert M. Toll Medical Student Research Prize	05/2001
Howard Hughes Medical Institute Predoctoral Fellow	06/1999

G. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation: Memorial Hospital for Cancer and Allied Diseases
2. Other Hospital Affiliation: none
3. Other Institutional Affiliations: Sloan-Kettering Institute

H. EMPLOYMENT STATUS

1. Current employer: **Memorial Sloan-Kettering Cancer Center**
2. Employment Status: **Full-time**
 - a. **Full-time salaried at Cornell-affiliated hospital**

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT

1. Teaching/Mentoring

Laboratory Mentorship:

Postdoctoral Fellows

Joachim Silber (10/2009-Present)
Kasthuri Kannan (05/2011-10/2013)
Gary Mason (08/2011-06/2013)
Joel Straughen (10/2012-09/2015)
Beatriz Aldaz-Arrieta (01/2013-04/2014)
Carla Danussi (06/2013-Present)
Yuxiang Wang (03/2015-Present)

Medical/Graduate Students

Daniel Gorovets (07/2010-07/2011)
Marcus Alexander (06/2010-08/2010)
Philippe Nguyen (06/2010-08/2010; 06/2011-08/2011)

Joe Hall (06/2012-08/2012)
Sara Franceschi (03/2013-12/2013)
Xiaojin Mu (05/2013-07/2013)
Rafael Klein-Cloud (06/2013-08/2013)
Yuemeng Mao (08/2013-09/2014)

Additional teaching/mentoring responsibilities:

I conduct Neuropathology seminars on a bi-monthly basis for the Departments of Neurology and Neurosurgery and a yearly Neuropathology review for New York Hospital Neurosurgery residents Board Exam preparation. Additionally, I regularly instruct and mentor fellows in the Department of Pathology during sign-out sessions. I also formally teach portions of the Gerstner Graduate School core curriculum (see itemized list below with hours/year; preparation time not included).

Neuropathology Seminars (6 hours)
Neuropathology Review (Cornell) (3 hours)
Gerstner Graduate School Core Curriculum (3 hours)
Pathology Fellows Core Curriculum (1 hour)
Neuro-oncology Fellows Core Curriculum (1 hour)
Pathology Fellow/Resident Mentorship (30 hours)
Core Course in Neuropathology (Cornell) (4 hours)

Research talks within the institution:

Translational Research Seminar: 11/2008
Brain Tumor Center (BTC) Seminar Series: 10/s009
Cancer Biology and Genetics/Human Oncology and Pathogenesis Program (CBG/HOPP) Science Club: 02/2010
Pathology Attending Rounds: 02/2010
BTC Retreat, Invited Presenter: 03/2010
Geoffrey Beene Cancer Research Retreat, Invited Presenter: 04/2010
Gerstner Graduate School Seminar Series: 05/2010
Department of Surgery Research Conference: 10/2010
Brain Tumor Center (BTC) Seminar Series: 11/2011
Head and Neck Core Course: 05/2012
BTC Retreat, Invited Presenter: 05/2012
Pathology Attending Rounds: 01/2013
Geoffrey Beene Cancer Research Retreat, Invited Presenter: 04/2013
HOPP Special Research Seminar, 05/2013
BTC Retreat, Invited Presenter: 09/2014

2. Clinical care

Attending Pathologist (Neuropathology and Autopsy): I attend regularly on the Neuropathology and Autopsy services. My routine duties include reading frozen sections, reviewing slide material and

issuing reports for the daily Neuropathology case load, and conducting brain cutting for autopsy specimens.

3. Administrative duties, including committees, dates

I have led the design and implementation of a standardized set of synoptic diagnoses for the vast majority of our pathology reports to facilitate databasing and clinical research. I am working to expand the use of standardized reporting for our correlative molecular testing as well. Finally, I have taken an advisory role in the development of a comprehensive clinical/research database for all Neuro-oncology patients at Memorial Hospital.

Additional committee memberships and service

Research Council (11/2011-present)

-Evaluating the scientific aspects of clinical protocols prior to IRB review.

Director, HOPP Automated Staining Facility (06/2013-present)

Brain Tumor Center Tissue Usage Committee (07/2009-present)

-Reviewing and approving investigational requests for human brain tumor tissue.

Brain Tumor Center Seminar Series, Director (07/2013-present)

Pathology Department Technology committee (11/2010-present)

-Investigating new technologies and advising the departmental leadership regarding their purchase and incorporation.

Pathology Research Committee (07/2015-present)

-Participate in triannual review of applications for intramural funding within the MSKCC

Department of Pathology

MSKCC Lung P01 internal review committee (Mark Kris, PI) (08/2011-present)

Thesis Committees

-Ken Pitter, Holland Lab (07/2010-06/2013)

-David Roy, Chan Lab (07/2012-06/2015)

4. Research Narrative

Assistant Member and Lab Head, Memorial Sloan-Kettering Cancer Center, 2009-present

My primary research interests involve the molecular pathogenesis of brain tumors, particularly malignant gliomas. The efforts of my laboratory are currently directed towards both basic science and more clinically oriented translational investigations.

Molecular pathogenesis of adult and pediatric glioma: Recently, mutations in isocitrate dehydrogenase enzymes (IDH1 and IDH2) have emerged as foundation molecular alterations driving lower-grade astrocytomas and oligodendrogliomas. While their precise pathogenic impact is still largely unknown, IDH mutations appear to promote both cellular epigenomic remodeling and the maintenance of stem cell-like physiology. Despite these profound biological effects, however, it remains unclear how IDH mutations themselves induce gliomagenesis. It seems highly likely,

therefore, that additional molecular events conspire with IDH mutation to drive tumorigenesis in lower-grade gliomas.

We recently identified loss-of-function mutations in the *ATRX*, which codes for an essential chromatin remodeling enzyme, in ~70% of IDH-mutant lower-grade astrocytic gliomas. Using a variety of *in vitro* and *in vivo* modeling systems, we are functionally characterizing the role of *ATRX* mutation in gliomagenesis, focusing particular attention on how *ATRX* deficiency affects epigenomic landscapes. We have found that *ATRX* deficiency dramatically alters chromatin accessibility genome-wide, with downstream effects on gene expression profiles. These changes are associated with the acquisition of cancer-relevant cellular phenotypes. We are now in the process of further characterizing the precise gene expression programs whose mobilization mediates *ATRX*-deficient transformative behavior. In parallel efforts, we are also determining the effects of *ATRX* deficiency on genomic instability and telomere maintenance.

Intriguingly, mutations in core H3.3 histone proteins have recently been identified in large numbers of pediatric gliomas, often in combination with *ATRX* mutations. This likely pathogenic involvement of epigenomic modifiers parallels adult glioma, and speaks to the compelling possibility of shared oncogenic mechanisms across tumor types. Accordingly, we are utilizing the same *in vitro* and *in vivo* modeling systems to functionally assess the impact of H3.3 and *ATRX* mutations in pediatric glioma.

microRNA (miRNA) biology: We have been studying the impact of miRNA-based gene regulation in the evolution of primary brain tumors for some time. miRNAs are small noncoding RNAs that mediate pre-translational repression of selected genes by binding loosely complementary sequences in target mRNAs, most commonly in their 3'-untranslated regions. Numerous miRNAs have been implicated in neoplastic processes, including brain cancers like glioma and medulloblastoma. We initially identified the miRNA miR-26a as a direct translational repressor of the tumor suppressor PTEN. Furthermore, we demonstrated that miR-26a is amplified at the genomic level in a significant portion of high-grade gliomas and that miR-26a-mediated PTEN regulation facilitates gliomagenesis *in vivo*.

More recently, we have been increasingly focused on characterizing miRNA networks influencing the development of lower-grade and so-called proneural glioma subtypes. In these investigations, we have shown that miR-34a and its direct target PDGFRA are involved in a feed-forward negative regulatory loop that promotes tumorigenesis in proneural gliomas. We are currently investigating other miRNAs involved in the potentiation of oncogenic networks and the maintenance of self-renewal capability in glioma cells of origin. Through these studies, we hope to identify pathogenic miRNA/mRNA interactions and the biological contexts in which they act, both of which may serve to facilitate therapeutic development.

Recurrent glioma biology and mechanisms of pathological progression: Malignant gliomas invariably recur following first-line interventions, frequently in a form resistant to conventional

therapies. In this way, the vast majority of patients with malignant glioma eventually succumb to recurrent disease that has undergone molecular and cellular evolution under the influence of cytotoxic, genome-modulating agents. We are investigating the biology underlying the behavior of treated malignant gliomas using a comprehensive integrated genomics approach is a large set of patient matched, pre- and post-therapy samples. Our studies will include whole exome sequencing, DNA copy number, transcriptomal, and global methylation analyses.

Correlative science for clinical trials: My group maintains in active presence in the molecular stratification of clinical trials. In these efforts, we aim to correlate response, survival, and other predetermined endpoints with specific molecular features and subclasses within patient tumor cohorts. Precise projects vary depending on the nature and extent of collaboration with relevant clinical services.

J. RESEARCH SUPPORT

1. Ongoing Research Support

Sontag Distinguished Scientist Award 10/01/2012-09/30/2016

“Elucidating the role of microRNA networks in the pathogenesis of lower-grade glioma”

The project will address the specific role of miR-34a in the pathogenesis of IDH mutant diffuse gliomas

Role: Principal Investigator

Amount: \$600,000

Doris Duke Clinical Scientist Development Award 07/01/2012-06/30/2015

“Evaluating the predictive potential of signature-based molecular subclasses in malignant glioma”

The project will test the predictiveness of specific expression signatures in the management of patients with malignant glioma.

Role: Principal Investigator

Amount: \$486,000

Cycle for Survival Research Grant 09/01/2015-08/31/2017

“Characterizing the epigenetic mechanisms driving ATRX-deficient gliomagenesis”

This project will investigate the epigenetic events that drive oncogenic transformation in the setting of ATRX deficiency, a common molecular alteration in IDH-mutant, lower-grade gliomas.

Role: Principal Investigator

Amount: \$400,000

1U54CA163167-01 (NCI) 09/01/2011-08/31/2016

“Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors”

This project investigates the role of stromal cells and vascular elements in the pathogenesis malignant primary and metastatic brain tumors.

Role: Director, Pathology Core (5% effort) (PI: Eric Holland)

Amount: \$4,781,785

2. Completed Research Support

Sidney Kimmel Translational Science Scholar Grant 07/2012-06/2014

“Investigating miRNA networks that promote proneural gliomagenesis”

This project focuses on the in vitro and in vivo functional characterization of specific miRNAs implicated in the pathogenesis of the proneural subtype of glioma.

Role: Principal Investigator

Amount: \$200,000

Brain Tumor Center Research Grant 08/2013-07/2014

“Therapeutically targeting ATRX deficiency in lower-grade astrocytoma”

The project aims to target the abnormal telomere maintenance mechanism and genomic instability inherent in ATRX-mutant lower-grade gliomas with specific therapeutic strategies.

Role: Primary Mentor (PI: Beatriz Aldaz-Arrieta, post-doctoral fellow)

Amount: \$100,000

AACR-Landon Innovator Award for Research in Personalized Cancer Medicine 07/2011-06/2013

“Personalizing PI3K/AKT Pathway Inhibitor Therapy in Malignant Glioma”

The project aims to optimize methods for the stratification of malignant glioma patients by PI3K/AKT pathway activation status and support clinical trials for pathway inhibitors.

Role: Principal Investigator

Amount: \$100,000

Brain Tumor Center Research Grant 08/2012-07/2013

“Elucidating the oncogenic effects of histone protein mutations in pediatric glioma”

The project aims to assess the functional consequences of pathogenic core histone protein mutations in cell line models of pediatric glioma.

Role: Primary Mentor (PI: Gary Mason, post-doctoral fellow)

Amount: \$100,000

Geoffrey Beene Center Research Grant 08/2010-07/2012

“A Comprehensive Genomic and Epigenomic Analysis of the Impact of First-Line Therapy in the Molecular Evolution of Malignant Glioma”

The project aims to comprehensively identify genomic and epigenomic abnormalities resulting from cytotoxic anti-cancer therapy in malignant glioma.

Role: Principal Investigator

Amount: \$400,000

Brain Tumor Center Research Grant 08/2011-07/2012

“Characterizing the pathophysiological significance of transcriptional subclass in WHO grade II and III diffuse astrocytoma”

The project aims to determine the functional and clinical importance of transcriptional signatures WHO grade II and III astrocytomas, particularly with regard to prognosis and potential cell(s) of origin.

Role: Principal Investigator

Amount: \$100,000

Geoffrey Beene Center Shared Resource Award 08/2010-07/2011
“High-Throughput Immunohistochemistry”

Funds the purchase of a high-capacity autostainer for immunohistochemistry to serve as a shared institutional resource

Role: Principal Investigator

Amount: \$232,000

Society for MSKCC Research Grant 07/2009-06/2011
“A Functional Analysis of microRNAs in Gliomagenesis”

The project is directed towards the functional characterization of specific miRNAs that enhance gliomagenesis through the regulation of tumor suppressor expression.

Role: Principal Investigator

Amount: \$200,000

Brain Tumor Center Research Grant 08/2009-07/2010
“Biomarker Development for molecular subclassification of malignant glioma”

The project was directed toward the identification and clinical implementation of mRNA, miRNA and protein biomarkers to facilitate the classification of malignant gliomas into molecularly defined treatment groups for targeted therapies.

Role: Principal Investigator

Amount: \$100,000

Geoffrey Beene Center Research Grant 08/2010-07/2012
“Identification of aberrant signal transduction pathways in Primary CNS Lymphoma”

This project is directed toward the identification of signaling pathway abnormalities in primary CNS lymphoma. Multilevel genomic and transcriptomal mechanistic analysis will also be performed.

Role: Co-Principal Investigator

Amount: \$400,000

Brain Tumor Center Research Grant 08/2009-07/2010
“Molecular Characterization and Stratification of Human Medulloblastomas”

The project was directed towards the development of methods for the molecular profiling and classification of medulloblastomas from formalin-fixed paraffin-embedded tissue.

Role: Co-Principal Investigator

Amount: \$100,000

Geoffrey Beene Center Research Grant 08/2009-07/2011
“Pulsatile kinase inhibitor therapy for malignant glioma: proof of concept clinical trial”
This project aims to determine whether high-dose pulsatile erlotinib therapy will be efficacious specifically against malignant gliomas harboring the EGFR vIII deletion mutation.
Role: Co-Principal Investigator
Amount: \$400,000

Revson/Winston Fellowship in Biomedical Research 07/2009-09/2009
“A Functional Analysis of microRNAs in Gliomagenesis”
The project was directed towards the functional characterization of specific miRNAs that enhance gliomagenesis through the regulation of tumor suppressor expression.
Role: Research Fellow primarily responsible for the design, execution, and interpretation of investigations.

David Tetenbaum Hope/American Brain Tumor Association Fellow 07/2006-06/2008
“A Study of the Role of microRNAs in Brain Tumor Pathogenesis”
The project was directed towards elucidating the functional relevance of brain tumor-implicated microRNAs in relevant in vivo model systems.
Role: Research Fellow primarily responsible for the design, execution, and interpretation of investigations.

Howard Hughes Medical Institute Pre-doctoral Fellowship 07/1999-12/2001

3. Pending Research Support (Applied)

American Cancer Society Research Scholar Grant 01/2017-12/2020
“Characterizing the epigenetic consequences of ATRX deficiency in cancer”
This project will systematically determine how ATRX deficiency contributes to transformative phenotypes in diffuse glioma by modulating epigenomic landscapes and gene expression.
Role: Principal Investigator
Amount: \$792,000

R01NS096336-01 04/2016-03/2021
“Characterizing the epigenetic mechanisms driving ATRX-deficient oncogenesis”
This project will systematically determine how ATRX deficiency contributes to transformative phenotypes in diffuse glioma by modulating epigenomic landscapes and gene expression.
Role: Principal Investigator
Amount: \$2,198,750

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

1. Invited Lectures

- “Biochemical and Morphological Characterization of BACE: The Alzheimer’s Disease β -Secretase,”; Society for Neuroscience 2000 Conference, 11/2000
- “Pathology of Adult Brain Tumors”; Fox Chase Cancer Center; 11/2008
- “The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis *in vivo*”; American Association of Neuropathologists Annual Meeting, 06/2009
- “MicroRNAs in Malignant Glioma”; HHMI Medical Fellows Northeast Regional Enrichment Event, New York University, 03/2011
- “Profiling Tumor Heterogeneity in the Real World: Molecular Annotation of Malignant Glioma in the Clinical Setting”; American Association for Cancer Research 2011 Conference, 04/2011
- “IDH1 mutation characterizes glioneuronal tumor with neuropil-like islands (GTNI)”; American Association of Neuropathologists Annual Meeting, 06/2011
- “Studying the molecular foundations of diffuse astrocytoma”; Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles, 09/2011
- “Molecular Neuropathology: From Genomic Profiles to Clinical Translation”; Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles, 02/2012
- “IDH Mutation and Neuroglial Developmental Features Define Distinct Subclasses of Lower-Grade Diffuse Astrocytic Glioma”; American Association of Neuropathologists Annual Meeting, 06/2012
- “Investigating the molecular foundations of lower-grade diffuse gliomas”; Department of Pathology, St. Jude Children’s Research Hospital, 11/2012
- “Translating TCGA findings to clinical biomarkers”; Society for Neuro-oncology Annual Meeting, Education Day, 11/2012
- “Molecular annotation of malignant glioma in the clinical setting”; Radiology Society of North America, Annual Meeting, 11/2012
- “Fashioning pre-clinical models for lower-grade glioma”; Accelerating Brain Cancer Cure (ABC²) Low Grade Glioma Research Workshop, 01/2013
- “The emerging molecular foundations of diffuse gliomas”; 2013 Neuro-Oncology Symposium, Hackensack University Medical Center, 05/2013
- “ATRX abnormalities are class-defining molecular determinants in lower-grade diffuse gliomas”; American Association of Neuropathologists Annual Meeting, 06/2013
- “Investigating the pathogenic mechanisms of lower-grade glioma”; Neurosurgical Grand Rounds, University of Washington Medical Center, 10/2013
- “Practical aspects of incorporating genotyping into clinical trials”; NCI- ABC² Scientific Meeting: Improving the treatment of glioblastoma, 09/2013
- “How recent molecular insights alter diagnostic conceptions of adult glioma”; Society for Neuro-oncology Annual Meeting, 11/2013
- “Linking classification and pathogenesis in lower-grade glioma”; Alvord Brain Tumor Center Seminar Series, Fred Hutchinson Cancer Research Center, 03/2014
- “Linking classification and pathogenesis in lower-grade glioma”; Mechanism of Personalized Medicine Seminar Series, Thomas Jefferson University Medical Center, 03/2014
- “Exploring the molecular foundations of diffuse gliomas”; New York University Medical Center, 05/2014

“Emerging developments in the molecular classification of diffuse gliomas”; Canadian Neuro-oncology Annual Meeting, Education Day, Halifax, Nova Scotia, 06/2014
“Characterizing the molecular foundations of lower-grade astrocytoma”; Canadian Neuro-oncology Annual Meeting, Plenary Session, Halifax, Nova Scotia, 06/2014
“Elucidating the oncogenic role of ATRX deficiency in glioma”; International Conference on Brain Tumor Research and Therapy, Lake Tahoe, 07/2014
“Functionally characterizing ATRX deficiency in glioma”; Brain Tumor Center Seminar Series, MD Anderson Cancer Center, 12/2014
“Investigating the molecular foundations of lower-grade astrocytoma”; Molecular Pathology Seminar Series, Johns Hopkins School of Medicine, 02/2015
“Functionally characterizing ATRX deficiency in glioma”; Department of Pathology Grand Rounds, MD Anderson Cancer Center, 04/2015
“Emerging molecular markers in primary brain tumors”; New York Pathology Society Annual Symposium, 05/2015
“Investigating the functional consequences of ATRX deficiency in glioma”; American Association of Cancer Research Advances in Brain Cancer Research Meeting, Washington, D.C., 05/2015
“Glioblastoma: molecular pathogenesis and biomarkers”; 2015 Current Trends in the Management of Malignant Gliomas: New Horizons in the Treatment of Brain Tumors, Xi’an, China, 09/2015
“Molecular classification of lower-grade gliomas”; 2015 Current Trends in the Management of Malignant Gliomas: New Horizons in the Treatment of Brain Tumors, Xi’an, China, 09/2015
“Investigating gliomagenesis in the age of –omics”; 5th Annual Brain Tumor Symposium, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 10/2015
“Case presentation of composite oligodendroglioma and astrocytoma”; United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Seattle, WA, 03/2016
“ATRX deficiency alters motility and differentiation in glioma cells of origin by dysregulating epigenomic landscapes”; International Conference on Brain Tumor Research and Therapy, Okinawa, 04/2016

2. Invited Positions at Scientific Meetings

“WHO classification of tumors update”; session chair, Society for Neuro-oncology annual meeting, 11/2013
“Molecular pathology for the clinician”; session chair, Society for Neuro-oncology annual meeting, 11/2014
“Molecular pathology-rapid reports”; session discussant, Society for Neuro-oncology annual meeting, 11/2015

3. Journal-Related Service

Neuro-oncology: Editorial Board member (2013-present); Regular contributor, Recent Advances in Neuro-oncology section (2013-present)
Acta Neuropathologica Communications: Editorial Board member (2013-present)

4. Manuscript Reviewer (Ad-Hoc)

Acta Neuropathologica (2010-present)
Brain Pathology (2008-present)
Cancer Research (2012-present)
Cell (2012-present)
Clinical Cancer Research (2009-present)
EMBO Journal (2011-present)
Glia (2008-present)
Histopathology (2011-present)
International Journal of Biochemistry and Cell Biology (2012-present)
Journal of Clinical Oncology (2015-present)
Journal of Molecular Diagnostics (2013-present)
Journal of Neuro-oncology (2013-present)
Journal of Neuropathology and Experimental Neurology (2010-present)
Journal of Pathology (2009-present)
Lancet Oncology (2013-present)
Modern Pathology (2015-present)
Molecular Cell (2013-present)
Nature Genetics (2015-present)
Nature Reviews Neurology (2012-present)
Neuro-oncology (2013-present)
New England Journal of Medicine (2011-present)
Oncologist (2011-present)
PLoS Genetics (2012-present)
PLoS ONE (2011-present)
Proceedings of the National Academy of Sciences (2013-present)
Virchows Archives (2012-present)
Scientific Reports (2016-present)

5. Grant Review

CDMRP (Department of Defense) Neurofibromatosis Award Study Section 09/2012, 09/2013

6.. Miscellaneous Administrative Service

The Cancer Genome Atlas, lower-grade glioma project: Principal Investigator, MSKCC; Member, analysis working group (2011-2015)

The Cancer Genome Atlas, GBM-LGG project: Member, analysis working group (2014-2016)

Society for Neuro-Oncology: Chair, young investigators committee (2011-2015); Chair, international outreach committee (2016-present); Member, strategic planning committee (2012-present)

International Adaptive Trial for Glioblastoma Multiforme (GBM): Member, Pathology/Biospecimens Committee (2015-present)

American Association of Neuropathologists: Awards Committee (06/2013)

Adult Brain Tumor Consortium: Member, Neuropathology Core Committee

Pediatric Brain Tumor Consortium: Member, Pathology Committee (2013-present)

Faculty of 1000: Faculty Member (2012-present)

BIBLIOGRAPHY

Peer- Reviewed Articles

1. **Huse, J.T.**, Pijak, D.S., Leslie, G.J., Lee, V.M.-Y., Doms, R.W. "Maturation and Endosomal Targeting of β -Site Amyloid Precursor Protein-cleaving Enzyme: The Alzheimer's Disease β -Secretase". (2000) *J Biol Chem* 2000;275:33729-33737.
2. **Huse, J.T.**, Liu, K., Pijak, D.S., Carlin, D., Lee, V.M.-Y., Doms, R.W. " β -Secretase Processing in the Trans-Golgi Network Preferentially Generates Truncated Amyloid Species That Accumulate in Alzheimer's Disease Brain". *J Biol Chem* 2002;277:16278-16284.
3. **Huse, J.T.**, Byant, D., Yang, Y., Pijak, D.S., D'Souza, I., Lah, J.J., Lee, V.M.-Y., Doms, R.W., Cook, D.G. "Endoproteolysis of β -Secretase (BACE) Within its Catalytic Domain: A Potential Mechanism for Regulation". *J Biol Chem* 2003;278:17141-17149.
4. Schessl, J., Medne, L., Hu, Y., Brown, M.J., **Huse, J.T.**, Torigian, D.A., Jungbluth, H., Goebel, H.H., Bonnemann, C.G. "MRI in DNM2-related centronuclear myopathy: Evidence for highly selective muscle involvement". *Neuromuscul Disord* 2006;12:28-32.
5. Chen, H.I., Burnett, M.G., **Huse, J.T.**, Lusting, R.A., Bagley, L.J., Zager, E.L. "Recurrent delayed cerebral necrosis with aggressive characteristics after radiosurgical treatment of an arteriovenous malformation". *J Neurosurg* 2006;105:455-460
6. Cardillo, S., **Huse, J.T.**, Iqbal, N. "Diabetic muscle infarction of the forearm in a patient with longstanding type I diabetes". *Endocr Pract* 2006;12:188-192.
7. Elmariah, S.B., **Huse, J.**, LeRoux, P., Lustig, R.A. "Multicentric glioblastoma multiforme in a patient with BRCA1 invasive breast cancer". *Breast J* 2006;12:470-474.
8. **Huse, J.T.**, Pasha, T.L., Zhang, P.J. "D2-40 Functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma". *Acta Neuropathol* 2006;113:87-94.
9. Whitmore, R.G., Krejza, J., Kapoor, G.S., **Huse, J.T.**, Woo, J., Bloom, S., Wolf, R.L., Judy, K., Rosenfeld, M., Biegel, J.A., Melhem, E.R., O'Rourke, D.M. "Prediction of oligodendroglial tumor subtype and grade using magnetic resonance perfusion-weighted imaging." *J Neurosurg* 2007;107:600-609.
10. Gasparetto, E.L., Pawlak, M.A., Patel, S.H., **Huse, J.T.**, Woo, J.H., Krejza, J., Rosenfeld, M.R., O'Rourke, D.M., Lustig, R., Melhem, E.R., Wolf, R.L. "Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction". *Radiology* 2009; 250, 887-896.
11. Perry, A., Miller, C. R., Gujrati, M., Scheithauer, B.W., Jost, S.C., Raghavan, R., Qian, J., Cochran, E.J., **Huse, J.T.**, Holland, E.C., Burger, P.C., Rosenblum, M.K. "Malignant Gliomas

- with Neuroblastic (PNET-like) Components (GBM-PNET): A Clinicopathologic and Genetic Study of 52 Cases”. *Brain Pathol* 2009; 19: 81-90.
12. Bleau, A.-M., Hambardzumyan, D., Ozawa, T., Fomchenko, E.I., **Huse, J.T.**, Brennan, C.W., Holland, E.C. “PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells”. *Cell Stem Cell* 2009; 4: 226-235
 13. **Huse, J.T.**, Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S.H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., and Holland, E.C. “The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis *in vivo*”. *Genes & Development* 2009; 23, 1327-1337.
 14. Becher O.J., Hambardzumyan D., Walker T.R., Helmy K., Nazarian J., Albrecht S., Hiner R.L., Gall S., **Huse J.T.**, Jabado N., MacDonald T.J., Holland E.C. “Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.” *Cancer Res* 2010; 70, 2548-2557.
 15. Ney, D.E., **Huse, J.T.**, Dunkel, I.J., Steinherz, P.G., Haque, S., Khakoo, Y. “Intraventricular Meningioma After Cranial Irradiation for Childhood Leukemia”. *J of Child Neurol* 2010; 25, 1292-1295.
 16. Ozawa, T., Brennan, C.W., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., **Huse, J.T.**, Pedraza, A., Utsuki, S., Yasui, Y., Tandon, A., Fomchenko, E.I., Oko, H., Levine, R.L., Fujii, K., Ladanyi, M., Holland, E.C. “PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.” *Genes & Development* 2010; 24, 2205-2218.
 17. Squatrito, M. Brennan, C.W., Helmy, K., **Huse, J.T.**, Petrini, J.H., Holland, E.C. “Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas”. *Cancer Cell* 2010; 18, 619-629.
 18. Fomchenko, E.I., Dougherty, J.D., Helmy, K.Y., Katz, A.M., Pietras, A., Brennan, C.W., **Huse, J.T.**, Milosevic, A., Holland, E.C. “Recruited cells can become transformed and overtake PDGF-induced murine gliomas *in vivo* during tumor progression”. *PLoS One* 2011; 6, e20605.
 19. Palaskas, N., Larson, S.M., Schultz, N., Komisopoulou, E., Wong, J., Rohle, D., Campos, C., Yannuzzi, N. Osbourne, J.R., Linkov, I., Kasthuber, E.R., Taschereau, R., Plaiser, S.B., Tran, C., Heguy, A., Wu, H., Sander, C., Phelps, M.E., Brennan, C.W., Port, E., **Huse J.T.**, Graeber, T.G., Mellinghoff, I.K. “¹⁸F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers”. *Cancer Res* 2011; 71, 5164-5174.
 20. **Huse, J.T.**, Nafa, K., Shulka, N., Kasthuber, E.R., Lavi, E., Hedvat, C.V., Ladanyi, M., Rosenblum, M.K. “High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas”. *Acta Neuropathol* 2011; 122, 367-369.
 21. Litkowski, P., Khakoo, Y., Gilheeny, S.W., Souweidane, M., **Huse, J.T.**, Haque, S., Young, R.J. “Hemangioma of the cavernous sinus in a child”. *Neurology* 2011; 77, 1647-1648.

22. Pulvirenti, T., Van Der Heijden, M., Droms, L.A., **Huse, J.T.**, Tabar, V., Hall, A. “Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas”. *Cancer Res* 2011; 71, 7280-7290.
23. Morris, L.G.T., Taylor, B.S., Bivona, T.G., Gong, Y., Eng, S., Brennan, C.W., Kaufman, A., Kasthuber, E.R., Banuchi, V.E., Singh, B., Heguy, A., Viale, A., Mellinghoff, I.K., **Huse, J.T.**, Ganly, I., Chan, T.A. “Genomic dissection of the EGFR/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers”. *Proc Natl Acad Sci USA* 2011; 108, 19024-19029.
24. Szerlip, N.J., Pedraza, A., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E.C., **Huse, J.T.**, Jhanwar, S.C., Leversha, M.A., Mikkelsen, T., Brennan, C.W. “Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response”. *Proc Natl Acad Sci USA* 2012; 109, 3041-3046
25. Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W.M., Lu, C., Ward, P.S., Thompson, C.B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L.G.T., **Huse, J.T.**, Mellinghoff, I.K., Chan, T.A. “IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype”. *Nature* 2012; 483, 479-483.
26. Gorovets, D., Kannan, K., Kasthuber, E.R., Islamdoust, N., Campos, C., Pentsova, E., Jhanwar, S.C., Heguy, A., Mellinghoff, I.K., Chan, T.A., **Huse, J.T.** “IDH mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower-Grade Diffuse Astrocytic Glioma”. *Clin Cancer Res* 2012; 18, 2490-2501.
27. Silber, J., Jacobsen, A., Ozawa, T., Harinath, G., Pedraza, A., Holland, E.C., Sander, C., **Huse, J.T.** “miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis”. *PLoS ONE* 2012; 7, e33844.
28. Shen, R., Mo, Q., Schultz, N., Seshan, V.E., Olshen, A.B., **Huse, J.T.**, Ladanyi, M., Sander, C. “Integrative Subtype Discovery in Glioblastoma using iCluster”. *PLoS ONE* 2012; 7, e35236.
29. Fischer, C., Haque, S.S., **Huse, J.T.**, Blochin, E., Souweidane, M.M., Lis, E., Khakoo, Y. “Extraneural Ependymoma: Distant Bone, Lung, Liver, and Lymph Node Metastases Following Bevacizumab”. *Pediatr Blood Cancer* 2012; 60, 143-145
30. Setty, M., Helmy, K., Khan, A.A., Silber, J., Arvey, A., Neezen, F., Agius, P., **Huse, J.T.**, Holland, E.C., Leslie, C.S. “Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma”. *Mol Syst Biol* 2012; 8, 605.
31. Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kasthuber, E.R., Heguy, A., Petrini, J.H., Chan, T.A., **Huse, J.T.** “Whole exome sequencing identifies *ATRX* mutation as a key molecular determinant in lower-grade glioma”. *Oncotarget* 2012; 3, 1194-1203.
32. Bazzoli, E., Pulvirenti, T., Oberstadt, M.C., Perna, F., Wee, B., Schultz, N., **Huse, J.T.**, Fomchenko, E.I., Voza, F., Tabar, V., Brennan, C.W., Deangelis, L.M., Nimer, S.D., Holland,

- E.C., Squatrito, M. “MEF promotes stemness in the pathogenesis of gliomas”. *Cell Stem Cell* 2012; 11, 836-844.
33. Binda, E., Visioli, A., Giani, F., Lamorte, G., Copetti, M., Pitter, K.L., **Huse, J.T.**, Cajola, L., Zanetti, N., Dimeco, F., De Filippis, L., Mangiola, A., Maira, G., Anile, C., De Bonis, P., Reynolds, B.A., Pasquale, E.B., Vescovi, A.L. “The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas”. *Cancer Cell* 2012; 22, 765-780.
34. Silber J., Hashizume R., Felix T., Hariono S., Yu M., Berger M.S., **Huse J.T.**, VandenBerg, S.R., James C.D., Hodgson, J.G., Gupta, N. “Expression of miR-124 inhibits growth of medulloblastoma cells”. *Neuro-Oncol* 2013; 15, 83-90
35. Omuro, A., Chan, T.A., Abrey, L.E., Khasraw, M., Reiner, A.S., Kaley, T.J., DeAngelis, L.M., Lassman, A.B., Nolan, C.P., Gavrilovic, I., Hormigo, A., Salvant, C., Heguy, A., Kaufman, A., **Huse, J.T.**, Panageas, K.S., Hottinger, A.F., Mellinghoff, I.K. “Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma”. *Neuro-Oncol* 2013; 15, 242-250
36. **Huse, J.T.**, Edgar, M., Halliday, J., Mikolaenko, I., Lavi, E., Rosenblum, M.K. “Multinodular and vacuolating neuronal tumors of the cerebrum: ten cases of a distinctive seizure-associated lesion”. *Brain Path* 2013; 23, 515-524.
37. Venneti, S., Felicella, M.M., Coyne, T., Phillips, J.J., Gorovets, D., **Huse, J.T.**, Kofler, J., Lu, C., Tihan, T., Sullivan, L.M., Santi, M., Judkins, A.R., Perry, A., Thompson, C.B. “Histone 3 lysine 9 trimethylation (H3K9me3) is differentially associated with isocitrate dehydrogenase 1 (IDH1) R132H mutations in oligodendrogliomas and high-grade astrocytomas”. *J Neuropath Exp Neurol* 2013; 72, 298-306.
38. Venneti, S., Garimella, M.T., Sullivan, L.M., Martinez, D., **Huse, J.T.**, Heguy, A., Sanit, M., Thompson, C.B., Judkins, A.R. “Evaluation of Histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas”. *Brain Path* 2013; 23, 558-564.
39. Young, R.J., Gupta, A., Shah, A.D., Graber, J.J., Schweitzer, A.D., Prager, A., Shi, W., Zhang, Z., **Huse, J.T.**, Omuro, A.M. “Potential role of preoperative conventional MRI including diffusion measurements in assessing EGFR gene amplification status in glioblastoma patients”. *Amer J Neuro-Rad* 2013; 34, 2271-2277.
40. Ho, A.S., Kannan, K., Roy, D.M., Morris, L.G.T., Ganly, I., Katabi, N., Ramaswami, D., Walsh, L., Eng, S., **Huse, J.T.**, Zhang, J., Dolgalev, I., Huberman, K., Heguy, A., Viale, A., Drobnjak, M., Leversha, M.A., Rice, C.E., Singh, B., Iyer, N.G., Leemans, C.R., Bloemena, E., Ferris, R.L., Seethala, R.R., Gross, B.E., Liang, Y., Sinha, R., Peng, L., Raphael, B.J., Turcan, S., Gong, Y., Schultz, N., Kim, S., Chiosea, S., Shah, J.P., Sander, C., Lee, W., Chan, T.A. “The mutational landscape of adenoid cystic carcinoma”. *Nat Genet* 2013; 45, 791-798.

41. Hatzoglou, V., Patel, G.V., Morris, M.J., Curtis, B.S., Zhang, Z., Shi, W., **Huse, J.T.**, Rosenblum, M.K., Holodny, A.I., Young, R.J. “Brain Metastasis from Prostate Cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis”. *J Neuroimaging* 2013. In press.
 42. Jacobsen, A., Silber, J., Harinath, G., **Huse, J.T.**, Schultz, N., Sander, C., with The Cancer Genome Atlas Research Network. “Analysis of microRNA target interactions across diverse cancer types”. *Nat Struct Mol Biol* 2013; 20, 1325-1332.
 43. Pyonteck, S.M., Schuhmacher, A.J., Bowman, R.L., Akkari, L., Sevenich, L., Olson, O.C., Teijeiro, V., Setty, M., Leslie, C., **Huse, J.T.**, Oei, Y., Holland, E.C., Daniel, D., Joyce, J.A. “CSF-1R inhibition alters macrophage polarization and blocks gliomagenesis”. *Nat Med* 2013; 19, 1264-1272.
 44. Aldaz, B., Sagardoy, A., Nogueira, L., Guruceaga, E., Grande, L., **Huse, J.T.**, Aznar, M.A., Diez-Valle, R., Tejada-Solis, S., Alonso, M.M., Fernandez-Luna, J.L., Martinez-Climent, J.A., Malumbres, R. “Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells”. *PLoS ONE* 2013; 8, e77098.
 45. Turcan, S., Fabius, A.W.M., Borodovsky, A., Pedraza, A., Brennan, C.W., **Huse, J.T.**, Viale, A., Riggins, G.J., Chan, T.A. “Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine”. *Oncotarget* 2013; 4, 1729-1736.
 46. Cairncross, G., Wang, M., Jenkins, R., Shaw, E., Giannini, C., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., **Huse, J.T.**, Mehta, M., Curran, W., for the Radiation Therapy Oncology Group (RTOG). “Benefit from PCV in oligodendroglial tumors is associated with mutation of *IDH*”. *J Clin Oncol* 2014; 32, 783-790.
 47. Kasthuber, E.R.*, **Huse, J.T.***, Berman, S.H., Pedraza, A., Zhang, J., Suehara, Y., Viale, A., Cavatore, M., Heguy, A., Szerlip, N., Ladanyi, M., Brennan, C.W. “Quantitative assessment and genomic context of intragenic receptor tyrosine kinase deletions in glioblastoma”. *Acta Neuropath* 2014; 127, 747-759.
- *co-first authors
48. Valiente, M., Obenauf, A., Jin, X., Chen, Q., Zhang, X.H.-F., Lee, D.J., Chaft, J.E., Kris, M.G., **Huse, J.T.**, Brogi, E., Massague, J. “Serpins shield brain metastatic cells from death signals and vascular detachment. *Cell* 2014; 156, 1002-1016.
 49. Huang, Y., Hoffman, C., Rajappa, P., Kim, J.H., Hu, W., **Huse, J.T.**, Tang, Z., Li, X., Weksler, B., Bromberg, J., Lyden, D., Greenfield, JP. “Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood brain barrier”. *Cancer Res* 2014; 74, 1011-1021.
 50. Pietras, A., Katz, A.M., Elstrom, E.J., Wee, B., Halliday, J.J., Pitter, K.L., Werbeck, J.L., Amankulor, N.M., **Huse, J.T.**, Holland, E.C. “Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth”. *Cell Stem Cell* 2014; 14, 357-369.

51. Gupta, A., Young, R.J., Shah, A.D., Schweitzer, A.D., Graber, J.J., Shi, W., Zhang, Z., **Huse, J.T.**, Omuro, A.M. “Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification”. *Clinical Neuroradiology* 2014. In press.
52. Gerber, N., Goenka, A., Turcan, S., Laufer, M., Makarov, V., Kannan, K., Beal, K., Omuro, A., Yamada, Y., Gutin, P., **Huse, J.T.**, Chan, T.A. “Transcriptional diversity of long-term glioblastoma survivors”. *Neuro-Oncol* 2014; 16, 1186-1195.
53. Ortiz, B., Fabius, A.W.M., Wu, W., Pedraza, A., Brennan, C.W., Schultz, N., Pitter, K.L., Bromberg, J., **Huse, J.T.**, Holland, E.C., Chan, T.A. “Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis”. *Proc Natl Acad Sci USA* 2014; 111, 8149-8154.
54. Ozawa, T., Riester, M., Cheng, Y.K., **Huse, J.T.**, Squatrito, M., Helmy, K., Charles, N., Michor, F., Holland, E.C. “Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor”. *Cancer Cell* 2014; 26, 288-300.
55. Omuro, A.M., Beal, K., Gutin, P., Karimi, S., Correa, D.D., Kaley, T.J., DeAngelis, L.M., Chan, T.A., Gavrilovic, I.T., Grommes, C., Reiner, A.S., Panageas, K.S., Baser, R.E., Tabar, V., Pentsova, E., Sanchez, J., Barradas-Panchal, R., Zhange, J., Brennan, C.W., Abrey, L.E., **Huse, J.T.** “Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma”. *Clin Cancer Res* 2014; 20, 5023-5031.
56. Oricchio, E., Papapetrou, E.P., Lafaille, F., Ganat, Y.M., Kriks, S., Ortega-Molina, A., Mark, W.H., Teruya-Feldstein, J., **Huse, J.T.**, Reuter, V., Sadelain, M., Studer, L., Wendel, H. “A cell engineering strategy to enhance the safety of stem cell therapies”. *Cell Reports* 2014; 8, 1677-1685.
57. **Huse, J.T.**, Diamond, E.L., Wang, L., Rosenblum, M.K. “Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true ‘oligoastrocytoma’?” *Acta Neuropath* 2015; 129, 151-153.
58. Kiess, A.P., Wolchok, J.D., Barker, C.A., Postow, M.A., Tabar, V., Huse, J.T., Chan, T.A., Yamada, Y., Beal, K. “Stereotactic radiosurgery for melanoma brain metastasis in patients receiving Ipilimumab: safety profile and efficacy of combined treatment”. *Int J Radiat Oncol Biol Phys* 2015; 92, 368-375.
59. Nayak, L., Panageas, K., Reiner, A.S., Huse, J.T., Pentsova, E., Braunthal, S.G., Abrey, L.E., DeAngelis, L.M., Lassman, A.B. “Radiotherapy and temozolomide for anaplastic astrocytic gliomas”. *J Neurooncol* 2015; 123, 129-134.
60. Moliterno, J., Cope, W.P., Vartanian, E.D., Reiner, A.S., Kellen, R., Ogilvie, S.Q., **Huse, J.T.**, Gutin, P.H. “Survival in patients treated for anaplastic meningioma”. *J Neurosurg* 2015; 123, 23-30.
61. Hechtman, J.F., Sadowska, J., **Huse, J.T.**, Borsu, L., Yaeger, R.D., Shia, J., Vakiani, E., Ladanyi, M., Arcila, M.D. “AKT1 E17K colorectal carcinomas show a pattern of concurrent

- mutations similar to PIK3CA kinase domain mutations and are associated with mucinous histology”. *Mol Cancer Res* 2015; 13, 1003-1008.
62. The Cancer Genome Atlas Research Network*. “Comprehensive and integrative genomic analysis of diffuse lower-grade gliomas”. *New England J of Med* 2015; 372, 2481-2498.
- *Active member of analysis working group and contributed substantially to writing and editing of the final manuscript.
63. Eckel-Passow, J.E., Lachance, D.H., Walsh, K.M., Decker, P.A., Hugues, S., Pekmezci, M., Molinaro, A.M., Rice, T., Kosel, M.L., Smirnov, I.V., Gobinda, S., Caron, A.A., Kollmeyer, T.M., Hansen, H.M., McCoy, L.S., Bracci, P.M., Marshall, R., Zheng, S., Reis, G., Pico, A., O’Neill, B.P., Buckner, J.C., Giannini, C., **Huse, J.T.**, Perry, A., Tihan, T., Berger, M.S., Chang, S.M., Prados, M., Wiemels, J., Wiencke, J.K., Wrensch, M.R., Jenkins, R.B. “TERT promoter mutation, IDH mutation and 1p/19q codeletion define five glioma molecular groups with specific clinical characteristics and germline variant associations”. *New England J of Med* 2015; 372, 2499-2508.
64. Lee, E.Q., Kaley, T.J, Duda, D.G., Schiff, D., Lassman, A.B., Wong, E.T., Mikkelsen, T., Purow, B.W., Muzikansky, A., Ancukiewicz, M., **Huse, J.T.**, Ramkissoon, S., Drappatz, J., Norden, A.D., Beroukhim, R., Weiss, S.E., Alexander, B.M., McCluskey, C.S., Gerard, M., Smith, K.H., Jain, R.K., Batchelor, T.T., Ligon, K.L., Wen, P.Y. “A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients”. *Clin Cancer Res* 2015; 21, 3610-3618.
65. Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T., Salama, S.R., Pagnotta, S.M., Murray, B.A., Morozova, E., Newton, Y., Wang, J., Brat, D.J., Zoppoli, P., Akbani, R., Cherniack, A.D., Zhang, H., Poisson, L., Mikkelsen, T., Yung, W.K.A., **Huse, J.T.**, Lau, C.C., Rao, A., Grifford, M., Wrensch, M., Beroukhim, R., Cooper, L., Rabadan, R., Aldape, K.D., Laird, P.W., Gutmann, D.H., Noushmehr, H., Iavarone, A., Verhaak, R.G.W., on behalf of TCGA Research Network. “Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma”. *Cell* 2016; 164, 550-563.
66. Butowski, N., Colman, H., De Groot, J.F., Omuro, A.M., Nayak, L., Wen, P.Y., Cloughesy, T.F., Marimuthu, A., Haidar, S., Perry, A., **Huse, J.T.**, Phillips, J., West, B.L., Nolop, K.B., Hsu, H.H., Ligon, K.L., Molinaro, A.M., Prados, M. “Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation early clinical trials consortium phase II study”. *Neuro Oncol* 2016; 18, 557-564.
67. Roy, D.M., Walsh, L.A., Desrichard, A., **Huse, J.T.**, Wu, W., Gao, J., Bose, P., Lee, W., Chan T.A. “Integrated genomics for pinpointing survival loci within arm-level copy number alterations”. *Cancer Cell*; 352, 737-750.
68. Quail, D.F., Bowman, R.L., Akkari, L., Quick, M.L., Schuhmacher, A.J., **Huse, J.T.**, Holland, E.C., Sutton, J.C., Joyce, J.A. “The tumor microenvironment underlies acquired resistance to CSF1R inhibition in gliomas”. *Science* 2016. In press.

69. Oktay, Y., Ulgen, E., Can, O., Akyerli, B., Yuksel, S., Erdemgil, Y., Durasi, I.M., Henegariu, O.I., Nanni, P., Selevsek, N., Grossman, J., Zeynep, E., Bai, H., Gupta, M., Lee, W., Turcan, S., Ozpinar, A., **Huse, J.T.**, Sav, M.A., Flanagan, A., Gunel, M., Sezerman, U., Yakicier, M.C., Pamir, M.N., Ozduman, K. "IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation". *Scientific Reports* 2016. In press.
70. Chakravarty, D., Pedraza, A., Cotari, J., Liu, A., Punko, D., Aushim, K., **Huse, J.T.**, Altan-Bonnet, G., Brennan, C.W. "Alliance of EGFR and PDGFRA in glioblastoma promotes tumor resistance to targeted therapy". *Cancer Discov* 2015. Submitted.

Reviews and Book Chapters

1. **Huse, J.T.**, Doms R.W. "Closing in on the Amyloid Cascade: Recent Insights into the Cell Biology of Alzheimer's Disease". *Mol Neurobiol* 2000;22:81-98.
2. **Huse, J.T.**, Doms R.W. "Neurotoxic Traffic: Uncovering the Mechanics of Amyloid Production in Alzheimer's Disease". *Traffic* 2001;2:75-81.
3. **Huse, J.T.** "Book Review: Neuropathology (Series title: Foundations in Diagnostic Pathology), Editor: Richard Prayson". *Human Pathol* 2006;37:244-245.
4. **Huse, J.T.**, Holland, E.C. "Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing". *Brain Pathology* 2009; 19, 132-143.
5. Bleau, A.-M., **Huse, J.T.**, Holland, E.C. "The Glioblastoma Resistance Network". *Cell Cycle* 2009; 8, 2936-2944.
6. **Huse, J.T.**, Holland, E.C. "Yin and yang: cancer-implicated miRNAs that have it both ways". *Cell Cycle* 2009; 8, 3611-3612.
7. **Huse, J.T.**, Holland, E.C. "Targeting Brain Cancer: Advances in the Molecular Pathology of Malignant Glioma and Medulloblastoma". *Nature Rev Cancer* 2010; 10, 319-331.
8. **Huse, J.T.**, Phillips, H., Brennan, C.W. "Molecular Subclassification of Diffuse Gliomas: Seeing Order in the Chaos". *Glia* 2011; 58, 1190-1199.
9. **Huse, J.T.**, Holland, E.C., DeAngelis, L.M. "Glioblastoma: molecular analysis and clinical implications". *Annu Rev Med* 2013; 64, 59-70
10. Kim, J.H., **Huse, J.T.**, Huang, Y., Lyden, D., Greenfield, J.P. "Molecular diagnostics in pediatric glial tumors". *Lancet Oncol* 2013; 14, e19-27.
11. **Huse, J.T.**, Aldape, K.D. "The molecular landscape of diffuse glioma and prospects for biomarker development". *Expert Opin Med Diagn* 2013; 7, 573-587.

12. **Huse, J.T.**, Wallace, M., Aldape, K.D., Berger, M.S., Bettgowda, C., Brat, D.J., Cahill, D.P., Cloughesy, T., Haas-Kogan, D.A., Marra, M., Miller, C.R., Nelson, S.J., Salama, S.R., Soffietti, R., Wen, P.Y., Yip, S., Yen, K., Costello, J.F., Chang, S. “Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma workshop”. *Neuro-Oncol* 2014; 16, 173-178.
13. **Huse, J.T.**, Jansen, M., Perry, A., Heffner, R.R., Louis, D.N. “Cancer of the Central Nervous System: Pathology and Molecular Genetics”. In *Bradley’s Neurology in Clinical Practice*; Ed. Pomeroy, S; Elsevier; Amsterdam. 7th Edition, Ch. 72.
14. **Huse, J.T.**, Aldape, K.D. “CMV and glioma-are we there yet?” *Neuro-Oncol* 2014; 16, 1433-1434.
15. **Huse, J.T.**, Aldape, K.D. “The evolving role of molecular markers in the diagnosis and management of diffuse glioma”. *Clin Cancer Res* 2014; 20, 5601-5611.
16. Alexander, B.M., Galanis, E., Yung, W.K.A., Ballman, K.V., Boyett, J.M., Cloughesy, T.F., Degroot, J.F., **Huse, J.T.**, Mann, B., Mason, W., Mellinghoff, I.K., Mikkelsen, T. Mischel, P., O’Neill, B.P., Prados, M.D., Sarkaria, J.N, Tawab-Amiri, A., Trippa, L., Ye, X., Ligon, K.L., Berry, D.A., Wen, P.Y. “Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group”. *Neuro-Oncol* 2015; 17, 180-188.
17. Venneti, S., **Huse, J.T.** “The evolving molecular genetics of low-grade glioma”. *Adv Anat Pathol* 2015; 22, 94-101.
18. **Huse, J.T.** “*TERT* promoter mutation designates biologically aggressive primary glioblastoma”. *Neuro-Oncol* 2015; 17, 5-6.
19. **Huse, J.T.**, Rosenbulum, M.K., “The emerging molecular foundations of pediatric brain tumors”. *J Child Neurol* 2015; 30, 1838-1850.
20. Von Diemling, A., **Huse, J.T.**, Yan, H., Brat, D.J., Reifenberger, G., Ohgaki, H., Kleihues, P., Berger, M.S., Weller, M., Nakazato, Y., Burger, P.C., Ellison, D.W., Louis, D.N. “Diffuse astrocytoma, IDH-mutant”. In *WHO Classification of Tumours of the Central Nervous System*; Ed. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K.; IARC, Lyon. Revised 4th Edition.
21. Von Diemling, A., **Huse, J.T.**, Yan, H., Brat, D.J., Ohgaki, H., Kleihues, P., Berger, M.S., Weller, M., Berger, P.C., Ellison, D.W., Rosenblum, M.K., Reifenberger, G., Paulus, W., Wesseling, P., Aldape, K.D., Louis, D.N. “Anaplastic astrocytoma, IDH-mutant”. In *WHO Classification of Tumours of the Central Nervous System*; Ed. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K.; IARC, Lyon. Revised 4th Edition.

22. **Huse, J.T.** “Establishing a robust molecular taxonomy for diffuse gliomas of adulthood”. Surg Path Clinics 2016. In press.

Date: 07/20/2016

Signature: _____